At last week’s American Chemical Society Spring meeting, Bristol Myers Squibb Co. discussed the development of a potent, orally bioavailable and highly selective cereblon (CRBN)-mediated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback